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Abstract
Background: In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still
being used in diagnosing malignant lymphomas (ML) and the biological characterization including the HIV/EBV
association is sketchy, thus restraining comparison, prognostication and application of established therapeutic
protocols.
Methods: Archival, diagnostic ML biopsies (N = 336), available sera (N = 35) screened by ELISA for HIV antibodies
and corresponding clinical/histological reports at Muhimbili National Hospital (MNH) in Tanzania between 1996 and
2006 were retrieved and evaluated. A fraction (N = 174) were analyzed by histopathology and
immunohistochemistry (IHC). Selected biopsies were characterized by flow-cytometry (FC) for DNA ploidy (N = 60)
and some by in-situ hybridization (ISH) for EBV-encoded RNA (EBER, N = 37).
Results: A third (38.8%, 109/281) of the ML patients with available clinical information had extranodal disease
presentation. A total of 158 out of 174 biopsies selected for immunophenotyping were confirmed to be ML which
were mostly (84. 8%, 134/158) non-Hodgkin lymphoma (NHL). Most (83.6%, 112/134) of NHL were B-cell
lymphomas (BCL) (CD20+), of which 50.9%, (57/112) were diffuse large B-cell (DLBCL). Out of the 158 confirmed
MLs, 22 (13.9%) were T-cell [CD3+] lymphomas (TCL) and 24 (15.2%) were Hodgkin lymphomas (HL) [CD30+].
Furthermore, out of the 60 FC analyzed ML cases, 27 (M:F ratio 2:1) were DLBCL, a slight majority (55.6%, 15/27)
with activated B-cell like (ABC) and 45% (12/27) with germinal center B-cell like (GCB) immunophenotype. Overall,
40% (24/60) ML were aneuploid mostly (63.0%, 17/27) the DLBCL and TCL (54.5%, 6/11). DNA index (DI) of FC-
analyzed ML ranged from 1.103-2.407 (median = 1.51) and most (75.0%) aneuploid cases showed high (>40%) cell
proliferation by Ki-67 reactivity. The majority (51.4%, 19/37) of EBER ISH analyzed lymphoma biopsies were positive.
Of the serologically tested MLs, 40.0% (14/35) were HIV positive, mostly with high (≥40.0%) Ki-67 reactivity.
Conclusions: According to the 2001 WHO Classification, most subtypes are represented in Tanzanian ML.
Extranodal presentation was common among MNH lymphoma patients who also showed high aneuploidy, tumor
proliferation (KI-67) and EBER positivity. DLBCL was frequent and phenotype heterogeneity appeared similar to
observations in Western countries suggesting applicability of established intervention approaches. HIV was
apparently associated with high ML cell proliferation but extended studies are needed to clarify this.
Background
Malignant lymphomas (ML) represent a spectrum
of lymphoid neoplasms with varying prognosis [1]
including non-Hodgkin lymphoma (NHL), Burkitt lym-
phoma (BL) and Hodgkin lymphoma (HL). MLs occur
worldwide with an increasing incidence both in indus-
trialized countries and Africa [1,2]. Lymphomas repre-
sent today an important cause of morbidity and
mortality in sub-Saharan Africa, including Tanzania
partly due to the HIV and AIDS epidemic [3-5].
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through the Rappaport Classification developed before
lymphoid cells were divided into B-cells and T-cells [6],
the International Working Formulation [WF] based on
clinical aggressiveness [6], the Kiel Classification (based
on histological grade) [7], the Lukes and Collins Classifi-
cation which separated B-cell and T-cell lymphomas by
immunologic techniques [8], the Revised European-
American classification of Lymphoid neoplasms [REAL]
[4] and most recently, the World Health Organization
[WHO] classification [9,10]. The later two classifications
recognize three major categories, B-cell neoplasms, T/
NK-cell neoplasms and HL [9]. For HL the Rye Classifi-
cation has been used for many years although, now
slightly modified in the WHO/REAL Classification sys-
tem [11,12]. Various countries have tested the applic-
ability and adopted the WHO classification [11,13]. In
Tanzania the WF is still used and attempts to apply the
WHO classification have so far not been documented.
Geographic and racial-ethnic differences in relative fre-
quency of various ML have been reported [5,9]. Such
geographic and racial-ethnic differences may influence
the adaptation of prognostication as well as therapeutic
protocols/algorithms shown to be effective elsewhere.
An update and re-appraisal of Tanzanian ML diagnoses
and characteristics possibly peculiar to this country is
therefore needed.
It is now well documented that ML in HIV and
AIDS patients also called AIDS-related lymphomas
(ARL) have distinct clinical features including frequent
extranodal presentation, which has not been evaluated
in Tanzanian ML patients before our current study
[4,14].
New insights into the pathogenesis of ML are continu-
ously gained with the development in cytogenetics,
molecular biology and immunological techniques [9].
Thus, similar to other cancers, ML may present with
genomic instability including specific translocations and
numerical chromosomal abnormalities (aneuploidy)
[15-17]. Furthermore, the ML association with different
viral infections is now well established including the
Epstein-Barr virus (EBV) [4,17,18], the human immuno-
deficiency virus (HIV) [4,17] and recently, Kaposi’ss a r -
coma associated herpes virus/human herpes virus type 8
(KSHV/HHV-8) in primary effusion lymphoma (PEL)
and multicentric Castleman’sd i s e a s e( M C D )y .H o w -
ever, the prevalence of such viral associations is still
sketchy in sub-Saharan Africa particularly Tanzania and
is elucidated in our current study [3-5].
Likewise, the diffuse large B-cell lymphoma (DLBCL)
group is now no longer one entity but rather a spectrum
of NHL with heterogeneous histopathology, genotype,
phenotype and prognosis including germinal center
B-cell like (GCB) and activated B-cell-like (ABC)
lymphomas [23,24]. Thus, the expression of proteins
related to germinal centre B (GCB) cell or activated B-
cells (ABC) and that of apoptosis-regulating proteins
have been found to be associated with clinical outcome
[25] and in particular Bcl-2 expression is strongly
related to poor prognosis [25].
Ki-67 expression by proliferating tumor cells is a well
established prognostic marker of malignancies including
ML [26,27]. Such prognostic markers are poorly docu-
mented in Africa including Tanzania [14] impeding the
development of comparable prognostication and adapta-
tion of corresponding therapeutic protocols emphasized
by our current studies.
Furthermore, data on clinical presentation and demo-
graphic (sex and age) characteristics for Tanzanian ML
are scanty [14]. Our recent report on ML tumor prolif-
eration included only mean values for major ML sub-
types [14]. Those data are extended by our current
long-term study
Methods
Study area
The study was conducted in the Histopathology Unit of
the Department of Laboratory Services at the Muhimbili
National Hospital (MNH) in Dar es Salaam, which is
also the teaching hospital for the Muhimbili University
of Health and Allied Sciences (MUHAS). MNH is the
national referral health care facility in Tanzanian with a
bed capacity of over 1000 and receives biopsies from
most of the country except the lake zone which has its
own manned pathology department.
Clinical presentation
This was retrieved from clinical records and was deter-
mined by physical examination, chest radiography and
abdominal ultrasonography during the study period.
Biopsies and HIV serology
Archival diagnostic biopsy material collected at MNH
between 1996 and 2006 (10 years) was reviewed for his-
topathology and analyzed by immunohistochemistry
(IHC), flow-cytometry (FC) and in-situ hybridization
(ISH) at the Immunopathology Lab (Karolinska Univer-
sity Hospital Solna, Stockholm). The fixation and tissue
processing protocols remained unchanged during the
study period. Biopsies were selected for IHC or FC
depending on the basis of representative tissue material
per block. Clinical notes and histological reports for all
ML biopsies submitted for diagnosis during the same
period were also evaluated. The clinical evaluation pro-
tocol did not change during the study period. HIV-1
antibody serology (ELISA) was performed at the Micro-
biology/Immunology department at Muhimbili Univer-
sity of Health and Allied Sciences (MUHAS) as
previously described [14,28].
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Primary histological diagnosis on hematoxylin and eosin
(H & E) stained formalin-fixed paraffin embedded
(FFPE) sections was done as previously described, at
MNH according to the International Working Formula-
tion [4,28].
Histopathological re-evaluation
(H & E and immunoperoxidase assay) of available tissue
blocks was done at Karolinska University Hospital Solna
independently and by three pathologists (ARM, PB and
AP) according to the 2001 WHO classification of lym-
phoid neoplasms [9]. Inter-observer discrepancies were
resolved by all three pathologists sitting together. Out of
the H & E-evaluated cases biopsies selected based on
the histological ML group, tumor:stroma ratio and
absent/minimal necrosis, were further evaluated by
immunohistology, cytomorphometry, flow-cytometry
and in-situ hybridization.
Immunohistochemistry (IHC)
Immunostaining was done (Immunopathology Lab) by
the avidin-biotin complex immunoperoxidase technique
as previously described [4,14,28]. Briefly, tissue sections
were mounted on SuperFrost® slides (Menzel GmbH &
Co KG, Braunschweigh, Germany) deparaffinized, rehy-
drated and boiled for antigen retrieval at 750W by
microwave (6 min) in citrate buffer pH 6. Endogenous
peroxidase activity was quenched by incubating the sec-
tions in 30% hydrogen peroxide in distilled water (30
min) at room temperature (RT) then followed by wash-
ing in phosphate-buffered saline (PBS) and incubation
with 1:20 normal serum from the species of the second-
ary antibody and washing (PBS). The sections were
incubated overnight at 4°C with primary antibody for
human antigens including pan-leucocyte CD45 (clone
LCA), B-cell CD20 (clone L26), Reed-Sternberg (RS)/
Hodgkin (HC) cells CD30 (clone Ber-H2), the Ki-67
(MIB-1) proliferation marker as well as the polyclonal
rabbit CD3 T-cell marker. For DLBCL sub-typing, the
immunophenotype of the tumors classified as germinal-
center B-cell like (GCB) or activated B-cell like (ABC)
lymphomas was determined using mouse anti-human
CD10 (SS2/36), MUM1p (clone MUM1p), BCL-6 (clone
PG-B6p) and BCL-2 (clone 124) all obtained from
DakoCytomation, (Glostrup, Denmark) were used. The
BCL-6/CD10/MuM1p markers were used for phenotypic
and the BCL-2/CD10/MuM1p antibodies for prognostic
sub-grouping. Thus DLBCLs could be categorized
into activated B-cell like (ABC) if they were CD10-/
BCL6+/MUM1p+, CD10-/BCL6- or CD10-/MUM1p+
and germinal center B-cell like (GCB) if they showed
CD10+, CD10-/BCL6+/MUM1p- or CD10-/MUM1p-
immunophenotypes. Furthermore, DLBCLs were
categorized into prognostic group 1 (favourable
prognosis) including all BCL-2- cases, BCL-2+/CD10+
and BCL-2+/CD10-/MUM1p- and group 2 (poor prog-
nosis) which included cases with BCL-2+/CD10-/
MUM1p+ reactivity [25]. For primary antibody detec-
tion, the sections were incubated (30 min, RT) with
anti-species (secondary) antibody and the avidin-biotin
complex respectively, and later developed (visualized)
with 3,3′-diaminobenzidine (DAB) chromogen (Sigma-
Aldrich, St. Louis MO, USA) as previously described
[4,14,28]. After PBS washing, the slides were lightly
counter-stained with H & E, blued in running tap water
(30 min), dehydrated in ascending grades of ethanol,
cleared in two runs of xylene and mounted with cover-
slips using Mountex (Histolab Products AB, Göteborg,
Sweden).
Negative controls included sections from tissues not
expressing the respective antigen as well as substitution
of the primary antibody by buffer. Positive controls
included tissue sections (lymph nodes and tonsils) with
known expression of the antigen under investigation.
These controls were included in each experiment.
Microscopic evaluation
A fluorescence microscope (Olympus BX60, Tokyo,
Japan) with a digital camera (Sony DKC-5000, Tokyo,
Japan) and various filter cubes was used to document
bright field and fluorescence microphotography. Cells
were scored on color micrographs in eight adjacent
fields (256 × 190 μm each) of characteristic lesions and
the mean count of DAB-positive cells for each primary
antibody (marker) was calculated. Strength of CD20
reactivity was subjectively scaled from 1+ to 4+ depend-
ing on staining intensity, thus intensity ≤2+ was
regarded as weak and intensity>2+ was regarded as
strong). Picture processing and printing was done using
Adobe Photoshop 7.0 (Adobe Systems Incorporated, San
Jose, USA) and Microsoft-Power Point, 2003 (Microsoft
Corporation, Redmond, WA, USA).
Tumor sample selection, enucleation and flow-cytometric
analysis (FC)
FC on extracted lymphoma and tonsillar nuclei was
performed as previously described [29]. Selected, non-
necrotic tumour regions containing ≥70% neoplastic
tissue in 90 μm thick sections were dissected, deparaffi-
nized, rehydrated and digested for 1 hour at 40°C with
0.1% w/v Sigma protease XXIV (Sigma P8038) [Sigma-
Aldrich, St. Louis, MO, USA] in Tris buffer [0.1 M Tris,
0.07 M NaCl (pH 7.2) [Merck, Darmstadt, Germany].
The obtained free nuclei in suspension were stained for
30′ with 6-diamidino-2-phenylindole (DAPI) solution
(10 μM DAPI in 800 mM disodiumhydrogenphosphate)
[Sigma D9542, Sigma-Aldrich, St. Louis, MO, USA] and
evaluated for DNA content by flow cytometry (≥2×1 0
4
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(Particle Analysing System)-cytometer (Partec, Münster,
Germany) and a LSRII Flow Cytometer (BD Biosciences,
San Jose, CA) were used. The ModFit Program (Verity
Software House; Topsham, ME, USA) was used for cell
cycle analysis. Ploidy [DNA index (DI)] of diploid and
aneuploid ML cell populations was compared to normal
tonsil cells as previously described [30,31].
Cytomorphometric evaluation
Extracted ML and control tonsillar nuclei were stained
with DAPI and mounted with Vectashield [Vector
Laboratories, Inc. Burlingame, CA, USA] mounting
medium for fluorescence microscopy on SuperFrost®
slides. The mean size (S) and pleomorphism (P) of
nuclei extracted from the tonsils were used as unity and
were termed S0 and P0. Thus relative nuclear size (RNS)
was the percentage size in excess of S0 evaluated as S0 +
size increase ≤25% = S1, S0 + increase of 26 - 50% = S2,
S0 + increase of 51 - 75% = S3 and S0 + increase
>75% = S4. Evaluation of nuclear pleomorphism was
P1 = mild, P2 = moderate and P3 = high. Mitotic figure
counts (MFC) were evaluated on routine H & E sec-
tions. High power field (HPF) refers to ×400 micro-
scopic magnification.
In-situ hybridization (ISH)
Epstein-Barr Virus (EBV) infection detection was done
by automated ISH as previously described [32] (Patho-
logy Cell analysis Lab, Cancer Center Karolinska) using
a fluorescein (FITC)-conjugated oligonucleotide probe
to EBV-encoded (EBER) transcripts on FFPE tissue sec-
tions optimized for use with Bond Polymer Refine
Detection (DS9800) and Anti-Fluorescein Antibody
(AR0833) on the Bond-max system (Leica Biosystems
Nussloch GmbH, Nussloch, Germany) according to the
manufacturer’s instructions.
Statistical analysis
Data was analyzed using Statistical Package for the
Social Sciences (SPSS) [SPSS Inc., Chicago Ill]. The
Fisher exact test was used for smaller sample sizes. P-
values of ≤ 0.05 were considered statistically significant.
Ethical considerations and MNH guidelines
These studies were approved by the MUHAS Research
Ethics Committee and the Ethical Committee, Karo-
linska University Hospital Solna (Dnr 01-096).
Upon obtaining individual informed consent and
upholding safety, confidentiality and privacy, patients
and material at MNH are also available for education
and research since it was established as a University
Teaching Hospital by an Act of Parliament. A strictly
confidential and coded specimen processing and
evaluation was conducted. HIV screening was performed
by clinicians upon informed consent in the respective
in-/out-patient units.
Results
ML frequency and general demography
During the period of study, the histopathology unit at
MNH received approximately 50,000 biopsies including
about 7,000 tumors out of which a total of 336 histolo-
gically diagnosed (H & E) lymphoma cases consecutively
collected were evaluated. In 311 of 336 cases the infor-
mation on patient sex (males 63.3%, n = 197/311 and
females 36.7%, n = 114/311) was available. In 281 of 336
cases the age of patients was known, including 107
(38.1%) children (≤18 years), 131 (46.6%) adults (19-54
years) and 43 (15.3%) elderly (≥55 years) (Table 1). The
overall age ranged from 4 to 91 years with a mean 31
and median of 30 years respectively.
Clinical presentation
Data on clinical presentation (based on physical exami-
nation, radiography, abdominal ultrasonography and
endoscopy) was available in 265 patients excluding cases
later ruled out as ML after histological and immunohis-
tological review. Majority 64.9%, (172/265) of these ML
had nodal and 35.1% (109) extranodal disease at diagno-
sis. Extranodal presentation was reported in just over
half (50.9%, 54/106) of childhood ML cases and in
20.9% (9/43) of the elderly, which difference was statisti-
cally highly significant (P = 0.00635, Chi-square Test)
[Table 2]. Anatomical sites of extranodal presentation
included visceral (12.5%), bone (10.0%) and soft tissues
(6.4%) while cutaneous, oral cavity, nasal and ocular in
descending order were rare. Furthermore, evaluation of
ML anatomical distribution showed that majority (57.7%
(153/265) had supra-diaphragmatic, 27.5% (73/265) sub-
diaphragmatic and 26.8% (71/265) disseminated lym-
phoma. However, no primary effusion lymphoma (PEL)
or primary central nervous system lymphoma (PCNSL),
were found in this cohort [Table 3]. Data on clinical
Table 1 General demographic characteristics of
confirmed malignant lymphomas (ML) at MNH between
1996 and 2006
Category Number of ML cases Percent
Available sex data 311/330 94.2
Female/Male 114/197 36.7/63.3
Available age data (years) 265/330 80.3
Juveniles (≤18y) 107 32.4
Adults (19-54y) 131 39.7
Elderly (≥55y) 43 13.0
Mean age 31.03 na*
*na = not applicable
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reviewed at the Immunopathology Lab [Table 4]. Differ-
ences in distribution of anatomical sites of disease
presentation by sex were not statistically significant
(p-value 0.4695, Chi-square Test) [Table 2].
Histology and immunohistochemistry (IHC)
A total of 174 biopsies out of the 336 cases above, were
selected and stained by H & E and immunoperoxidase
assay (IHC) based on availability of clinical notes, tissue
blocks as well as quantity of material per block. After
histopathological review and immunophenotyping using
a panel LCA, CD20, CD3 and CD30 cell markers, a
total of 158/174 were confirmed to be ML and 16 cases
(9.2%) were excluded from further ML sub-classification,
DNA ploidy and EBER studies but retained in the gen-
eral study cohort to account for misdiagnosis. These
represented mostly poorly differentiated metastatic car-
c i n o m a sa n ds a r c o m a si nl y m p hn o d e sa sw e l la sn e u -
roendocrine tumors (carcinoids) but also a few cases of
chronic inflammation including follicular hyperplasia
and tuberculosis. Furthermore, the evaluation revealed
134 (84.8%) NHL, including 112 (83.6%) B-cell lympho-
mas (BCL) [CD20+, CD3-] and 22 (13.7%) mature T-cell
lymphomas (TCL) [CD3+, CD20-] (Table 4). Most of
the reviewed BCLs, (50.9%, 57/112) were DLBCL [Figure
1(a-d)], 20.5% (n = 23) were BL [Figure 2(a-d)] and
28.6% (n = 32) were other B-cell lymphomas [Table 4],
which included small cell (SCL), lymphoplasmacytic
(LP), follicular (FL) and marginal zone B-cell lympho-
mas (MZBCL) as well as plasmacytoma and oral plasma-
blastic lymphoma (OPBL). However, primary
mediastinal large B-cell lymphoma was not found. TCL
included peripheral T-cell lymphoma, extranodal NK/T-
cell lymphoma (nasal type), angioimmunoblastic T-cell
lymphoma as well as anaplastic large-cell lymphoma.
Furthermore, 15.2% (n = 24) cases were HL (CD30+)
[Table 4]. As expected, majority (53.6%, n = 15/28) B-
cell lymphomas (BCL) with extranodal presentation
were BL cases and most (80.0%, 28/35) NHL with extra-
nodal presentation were TCL [Table 4]. Of the reviewed
HL cases (Table 5), most showed a classical HL (CHL)
histopathology) often of the mixed cellularity (MC) sub-
type [Figure 3(a)]. Furthermore, 6 (25.0%) cases were
CHL nodular sclerosis (NS), 3 (12.5%) lymphocyte rich
(LR) and 2 (8.3%) were lymphocyte depleted (LD). The
non-classical nodular lymphocyte predominant Hodgkin
lymphoma (NLPHL) subtype appeared rare (8.3%, 2/24)
[Table 5] in this cohort.
DLBCL sub-typing
Of the 27 subtyped DLBCL (M:F ratio 1.7:1) cases, 3
(11.1%) were diagnosed in children and 24 (88.9%) in
adults (Table 6). When sub-grouped for histological pre-
sence/absence of follicular structures most (74.1%) cases
(n = 20) showed completely diffuse architecture and
25.9% (n = 7) had follicular remnants (Table 6). Using
CD10, MUM1p, and BCL-6 markers together, we found
that slightly more DLCBL in our series showed an ABC
immunophenotype (55.6%, n = 15), by comparison to
GCB immunophenotype 44.4% (12) although this was
not statistically significant (P = 0.547, Chi
2 test) [Table
6]. As expected, all DLBCL with follicular remnants
were GCB and most (75.0%) of those completely diffuse
were ABC. The DLBCL immunophenotypes were asso-
ciated with varying strength of CD20 reactivity and
majority (57.1%, 12/21) of cases with strong reactivity
were GCB (p = 0.02). Thus most (70.4%, 19/27) DLBCL
examined were group 1 and 29.6% (8/27) were group 2
according to BCL-2/CD10/MuM1p sub-grouping (Table
6). In the present cohort, DLBCL subtype was not sig-
nificantly correlated to age-group, HIV serostatus,
tumor proliferation (Ki-67+) or DNA index/ploidy status
which however, could depend on the small sample size.
Cell proliferation by Ki-67 immunohistochemistry and
flow-cytometry (FC)
As expected, the highest (mean = 91.5%, range 75-98%)
reactivity was found among BL cases [Figure 2(c)]
Table 2 Anatomical presentation of ML by age-group at
MNH from 1996-2006
Age (Years) Anatomical presentation
[No. (%)]
Total
[No. (%)]
P-value
Nodal Extra-nodal
Young (≤18) 52 (33.1) 54 (50.0) 106 (40.0) 0.00635
Adults (19-54) 71 (45.2) 45 (41.7) 116 (43.8)
Elders (≥55) 34 (21.7) 9 (8.3) 43 (16.2)
Total 157 (59.2) 108 (40.8) 265 (100.0)
Female 58 (36.9) 45 (41.7) 103 (38.9) 0.4695
Male 99 (63.1) 63 (58.3) 162(61.1)
Total 157 (100.0) 108 (100.0) 265 (100.0)
NB: 265 is the number of confirmed ML whose clinical data was available
Table 3 Anatomical site of disease presentation at
diagnosis among TZ ML patients at MNH from 1996-2006
Anatomical site Number of ML cases Percent
Lymph node 157 59.2
Soft tissues 17 6.4
Oral cavity 8 3.0
Skin 9 3.4
Bone 28 10.6
Viscera 35 13.2
Ocular 4 1.5
Nasal 7 2.6
Total 265 100.0
NB: 265 is the number of confirmed ML whose clinical data was available
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10-90%, SD 23.5) and closely by TCL (mean 42.3%,
median 50.0%, range 10-80%, SD 24.2) and lowest for
HL [Figure 3(b)]. Furthermore, possible associations
between Ki-67 index, sex, age or clinical presentation of
ML cases as well as with that of different DLBCL sub-
types, were not statistically significant. However, as
expected, most (88.9%, 8/9) aneuploid ML cases showed
high tumor proliferation rates (>40% Ki-67 reactivity)
while only 11.1% of diploid ML had high tumor prolif-
eration which difference appeared to be statistically sig-
nificant (p-value 0.04, Fisher’s Exact Test). FC S-phase
Fraction (SPF) showed a mean for all ML of 19.6%
(median = 16.5%) ranging from 3.8-39.7%. Comparison
between Ki-67 index and SPF showed a significant cor-
relation (R
2 = 0.55) between the mean SPF and Ki-67
reactivity.
Epstein-Barr virus (EBV)
EBER in-situ hybridization (ISH) [Figures 2(d) &3(c)]
was evaluated on 37 ML cases of which the majority
(51.4%) were positive (19/37). Most (68.4%) of the
EBER+ cases were found in the adult age-group (13/19)
followed by juveniles (26.3%, 5/19) and rare in the
Table 4 Anatomical presentation of ML at diagnosis (MNH) by their reviewed histological subtypes (1996 -2006)
Reviewed histological
diagnosis
Anatomical Site
[No. (%)]
Reviewed cases with available
clinical data
Clinical data
unrecorded
Sub-
totals
Total reviewed
ML
Nodal Extranodal [No. (%)] [No. (%)] [No. (%)] [No. (%)]
DLBCL 35
(64.8)
7 (25.0) 42 15 57 (50.9)
BL 2 (3.7) 15 (53.6) 17 6 23 (20.5)
Other BCL* 17
(31.5)
6 (21.4) 23 9 32 (28.6)
Total BCL 54
(83.1)
28 (80.0) 82 30 112
(83.6)
112 (83.6)
TCL 11
(16.9)
7 (20.0) 18 4 22 (13.7)
TOTAL NHL 65
(65.0)
35 (35.0) 100 34 134 (84.8)
HL 10
(66.7)
5 (33.3) 15 9 24 (15.2)
TOTAL REVIEWED ML
[No. (%)]
75
(65.2)
40 (34.8) 115 (72.8) 43 (27.2) 158 (100.0)
*BCL = B-cell lymphomas
Figure 1 (a, b, c, d)- Sections of an activated B-cell like (ABC)
diffuse large B-cell lymphoma (DLBCL) case showing (a) H & E
staining, and granular membranous and cytoplasmic
immunoperoxidase (brown) reactivity in all tumor cells for (b)
CD20 antigen, (c) BCL-6 antigen and (d) BCL-2 antigen (all
×400).
Figure 2 (a, b, c, d)- H & E and immunoperoxidase staining
(brown) of a BL case showing (a) H & E section with “starry
sky pattern,” (b) granular membranous and cytoplasmic
reactivity in all tumor cells for CD20 antigen, (c) a high
proportion of nuclear Ki-67 immunoreactivity (brown) and (d)
EBER probe (dark brown) in situ hybridization (ISH) nuclear
reactivity in all tumor cells, (all ×400).
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cally significant (p = 0.048). EBER reactivity was not
correlated with either of the DLBCL immunohistological
subtypes, p = 0.87 (not statistically significant, Chi-
square test). Furthermore, EBER positivity correlation
with sex, clinical presentation, tumor proliferation
(Ki-67) and DNA index (DI) was also not statistically
significant.
Cytomorphometry results
DAPI-stained nuclei from 60 selected out of the 158
evaluated ML as well as from 3 tonsils were examined
microscopically for changes in nuclear size, shape pleo-
morphism and cellularity (Figure 4) and as expected the
highest nuclear size (S4) was most frequently seen in
H Lc a s e sw h i l ead i f f e r e n c eo fn u c l e a rp l e o m o r p h i s m
(NP) and for DI between different ML groups did
not appear to be statistically significant. Obviously,
Table 5 Histological subtypes of reviewed Hodgkin
lymphoma (HL) cases from MNH between 1996 and 2006
Histological diagnosis Number Percent
Classical HL (CHL)
Mixed cellularity (MC) 11 45.8
Nodular sclerosing (NS) 6 25.0
Lymphocyte rich (LR) 3 12.5
Lymphocyte depleted (LD) 2 8.3
Non-classical HL
Nodular lymphocyte predominant (NLPHL) 2 8.3
Total HL 24 100.0
Figure 3 (a, b, c,)- HL histologic sections: (a) H & E staining of
a classical HL mixed cellularity (MC) case showing Reed-
Sternberg (RS) cells (black arrow), eosinophils (blue arrow) and
lymphocytes (purple arrow), (b) nuclear Ki-67
immunoperoxidase reactivity (brown) in an RS cell, and (c) an
EBER positive (brown) RS cell (all ×400).
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Page 7 of 12cellularity (number of nuclei/hpf) appeared significantly
higher in BL followed by DLBCL, TCL and least in HL
and appeared to correlate well with the median Ki-67
immunoreactivity.
Flow cytometric (FC) results
The nuclei extracted from the 60 selected cases evalu-
ated by cytomorphometry above [including 27 DLBCL,
7 BL, 4 other B-cell lymphomas (BCL), 11 TCL and 11
H L ]a sw e l la st h o s ef r o mt h r e en o r m a lt o n s i l sw e r e
analyzed for DNA index (DI) and tumor proliferation
[S-Phase fraction (SPF)]. Microdissection and/or laser-
capture microscopy (LCM) could not be done for HL
cases in the current study due to logistical limitations.
Thus, the HL ploidy results presented hereinafter are
expected to serve as a proxy for HL cases at MNH. All
the tonsillar controls were euploid or diploid (DI = 1)
[Figure 5 (a)] but also some DLBCL [Figure 5(b)] and
other BCL (including BL) as well as some TCL and
most HL. Overall, 40% (24/60) of the selected ML cases
showed DNA aneuploidy and the highest (63.0%, 17/27)
frequency was seen in the DLBCL group followed by
TCL (54.5%, 6/11) while aneuploidy was rare (14.3%, 1/
7) in BL cases respectively, which differences were not
statistically significant (p-value 0.062, Chi
2 test). Aneu-
ploid DNA indices (DI) for tested ML biopsies ranged
from 1.103 to 2.407 (mean = 1.65, median = 1.51, SD =
0.445). About 37.5% (n = 8) aneuploid cases were hyper-
diploid (1 > DI < 1.3) mostly DLBCL (77.7%, 7/8) [Fig-
ure 5(c)] but also one TCL (12.5%) [Figure 5(d)]
(p = 0.369, not statistically significant). Furthermore,
only 12.5% (n = 3/24) of aneuploid ML cases showed
triploidy (1.3 ≥ DI < 1.7) including two DLBCL [Figure
6(a)] and one BL whereas 50.0% were tetraploid/multi-
ploid (DI ≥ 1.7) [12/24] including DLBCL (58.3%, n = 7)
[Figure 6(b)] and TCL (41.7%, n = 5) [Figure 6(c)]. Thus
tetraploidy appeared to be more (83.3%, 5/6) frequent
among TCL cases compared to DLBCL (47.1%, 7/17)
which difference was not statistically significant
(p = 0.161, Fisher Exact Test).
ML association with HIV infection (serology)
HIV screening was possible in only 22.2% (35/158) of
the histologically reviewed ML cases of which 40.0%
(14/35) were seropositive. Apparently, most (85.7%, 12/
14) of the positive cases were seen in the younger adults
(age 18-54). Furthermore, most (77.8%, 7/9) of the HIV
seroreactive ML stained for Ki-67 showed high (≥40.0%)
reactivity, which difference was statistically significant
(p = 0.021, Fisher’s Exact Test) [Figure 6(d)]. HIV asso-
ciation with sex, clinical presentation (disease extent
and anatomic location), EBV infection (EBER+ ISH),
and DNA index (ploidy) of ML cases appeared not sta-
tistically significant which could be due to small
samples.
Discussion
The ML demographics found in the studied, extended
10 year cohort are generally consistent with age and
sex distribution of Tanzanian lymphomas discussed in
our previous reports [4,14]. The finding that about
one-third of the ML had extranodal presentation at
diagnosis is of therapeutic importance and remarkably
concordant with the 30-40% extranodal presentation
observed among DLBCLs in Wurzburg, Germany [33]
but not previously documented in Tanzania and in
contrast to the frequency reported in Japan where
extra-nodal presentation was higher (83.3%) in the
young than (60.0%) in the older age-group [34]. Con-
cordant with our findings in juvenile ML cases [34],
nodal versus extranodal presentation is reportedly an
important factor for determination of ML prognosis
and pathogenicity related to genotypic and phenotypic
differences in the two clinical groups which however is
not well established [35]. Thus it seems that nodal and
extranodal DLBCL, as well as DLBCL from different
primary sites, are heterogeneous with regard to differ-
ent biologic characteristics and prognostic implications
[35]. Corresponding to other studies [36,37] we also
found that TCL were more often associated with extra-
nodal presentation particularly cutaneous and nasal
compared to other ML subtypes [36,37].
Lymphoma classification remains a challenge particu-
larly to resource-limited countries in Africa, where
methods complementary to routine histology such as
Figure 4 (a, b, c)- DAPI stained nuclei from a (a) normal
paraffinized tonsil showing relative monomorphism and from
DLBCLs showing pleomorphism (b & c) and mitoses (b).
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Page 8 of 12IHC, FACS, PCR and cytogenetics are mostly lacking.
This is also the reason why the WHO classification has
been difficult to implement in Tanzania. As realized
from the present study combined immunophenotyping
and H & E staining, clearly improved diagnostic specifi-
city and should be implemented routinely. Thus the
diagnosis of TCL by IHC in the current ML cohort to
our knowledge is novel in Tanzania. Furthermore, the
dominance of B-cell lymphomas, mostly DLBCL also
reported in our previous study [14], and the proportions
of BL, TCL and HL at MNH appear similar to other
studies [9] suggesting the applicability of the WHO clas-
sification for Tanzanian ML.
The sub-phenotyping of African DLBCL by IHC using
CD10, MUM1p and BCL-6 as well as BCL-2 cell mar-
kers in the present study has not our knowledge, been
reported before in Tanzania and Africa. Thus, our find-
ings indicate that previously established DLBCL sub-
phenotypes also exist in Tanzania/Africa, which should
allow the application of the same prognostication
criteria and therapeutic protocols as those in developed
countries. The apparently higher frequency of the ABC
than GCB lymphomas, in the current MNH cohort
appear to be concordant with several DLBCL studies
from North America and Western Europe [23,25]
although our sample size was small. However, this con-
cordance may support the notion of pathogenic and
biological similarity between Caucasian and African
DLBCL heterogeneity. Our finding of architectural (his-
tological) differences between diffuse DLBCL and those
with follicular remnants suggests also the existence of
DLBCL which may develop from nodal follicular
lymphoma (FL) [38].
Furthermore, the application of the WHO classifica-
tion of Tanzanian HL in the current study is novel
including the reporting of classical (CHL) and the non-
classical nodular lymphocyte predominant (NLPHL)
cases. However, our HL findings of more frequent
mixed cellularity (MC) than nodular sclerosing (NS)
among cases with CHL, were not in agreement with
Figure 5 (a, b, c, d)- DNA histograms of a diploid normal tonsil control (a), diploid (b) and hyperdiploid (c) DLBCLs as well as a
hyperdiploid TCL (d).
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Page 9 of 12reports from other countries were NS is reportedly more
common [39,40] although other reports seem to concur
with our current findings [11,41,42]. The reason for this
d i s c r e p a n c ya r en o tc l e a rb u tt h em a yp o s s i b l yi n c l u d e
the role of HIV infection in altering the epidemiology,
pathogenesis and natural history of HL [41,42] consider-
ing that Tanzania is within the epicenter of the HIV and
AIDS pandemic. However, these results could also
depend on the sample size.
The 40% rate of aneuploidy found among the Tanza-
nian ML patients indicates a relatively high prevalence
of genomic instability (chromosomal aberrations) and is
in general in agreement with previous reports from
Western countries [43,44] but higher than that observed
among NHL in a Swedish report [16]. High DNA
indices (triploidy, tetraploidy and multiploidy) were also
found in our current study as well as a high mean DI
comparable to other reports [16,45], which appears to
correlate with biological aggressiveness and poor prog-
nosis. The high DI (tetra-/multi-ploidy) and proportion
of aneuploidy found most frequently among the current
DLBCL cases is concordant with previous reports [45].
However, the lack of aneuploidy among our HL cases is
in contrast to other reports [46] and could probably be
due to the fact that microdissection/LCM for the neo-
plastic Reed-Sternberg cells (RSC) and/or Hodgkin cells
(HC) was not done in our current study due to resource
limitations as well as difficulty in suspending intact RSC
known to be aneuploid. The strong correlation between
aneuploidy and tumor proliferation (Ki-67) found in our
study was expected as previously reported by others
[47] and is indicative of a biological high tumor grade.
There was no association between aneuploidy and HIV
infection in our cohort but previous reports suggested
higher proliferation and lower DI among HIV-associated
lymphomas [44]. However, these reports are scanty, and
further documentation is needed [48]. Furthermore, the
finding that EBER positivity in our cohort, did not
appear to be clearly associated with high tumor prolif-
eration (Ki-67) could partly be due to the small sample
Figure 6 (a, b, c, d)- DNA histograms of triploid (a) and tetraploid (b) Tanzanian DLBCLs, a tetraploid TCL (c), as well as a histogram
of median Ki-67 reactivity (proliferation) and HIV serostatus in Tanzanian ML patients (d).
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our ISH-tested biopsies indicates a significant associa-
tion of lymphomas with EBER positivity at MNH parti-
cularly in the adult age-group (68.4%) and is consistent
with our previous report [4], in which we also showed
co-expression (31.8%) of tumoral EBV-encoded
R N A( E B E R )a n dH H V - 8D N A( P C R )b u tn o tM Lc e l l
HHV-8 latency-associated nuclear antigen (LANA) asso-
ciation [4].
The finding that increased tumor proliferation in our
current cohort appeared correlated to HIV infection, is
concordant with previous reports [44] and supports the
notion of viral-associated/driven tumor proliferation as a
biological role in the oncogenesis of HIV-related malig-
nancies similar to that reported for HHV-8 and Kaposi’s
sarcoma [28].
Conclusions
The WHO Classification can apparently be applied for
the diagnosis of lymphomas at MNH in Tanzania.
Extranodal presentation of ML was frequent particularly
for TCL. DLBCL subtype phenotype heterogeneity and
frequency was similar to that observed in Western
countries suggesting applicability of similar, diagnostic,
prognostic and therapeutic approaches. Lymphomas at
MNH appear to have frequent aneuploidy and EBER
positivity as well as high DNA indices and tumor prolif-
eration (Ki-67). HIV is apparently associated with
increased ML cell proliferation but extended studies are
needed to confirm this.
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